Introduction {#Sec1}
============

Breast cancer is one of the most prevalent invasive cancers and the second leading global cause of cancer-related deaths among women, in both developed and developing countries, which has become a major public health challenge \[[@CR1], [@CR2]\]. Global breast cancer incidence has been increasing by more than one million new cases every year; the incidence is significantly higher in developed countries than in developing countries \[[@CR3]\]. Breast cancer increased significantly in China, especially in Beijing and Shanghai; it increased by 23 and 31 % within 10 years, respectively. It is close to the levels of western high-prevalence countries of breast cancer \[[@CR4]\]. The mechanism of breast carcinogenesis is still not fully understood. Some factors such as familial history of the disease, age of menarche and menopause, diet, reproductive history, high estrogen exposure, and genetic factors are considered to be risk factors for breast cancer. There are studies suggesting that the effect determined by low-penetrance genes may provide a plausible explanation for breast cancer susceptibility, and in recent years, several common low-penetrance genes have been identified as potential breast cancer susceptibility genes \[[@CR5]--[@CR9]\].

As one of the important low-penetrance genes, 5,10-methylenetetrahydrofolate reductase (*MTHFR*) encodes a critical enzyme for intracellular folate homeostasis and metabolism, which catalyzes the conversion of 5,10-methylenetetrahydrofolate (5,10-methylene-THF) to 5-methyltetrahydrofolate (5-methylene-THF), and it is thought to influence DNA methylation and nucleic acid synthesis \[[@CR10]--[@CR12]\]. The *MTHFR* polymorphisms were considered to be associated with breast cancer susceptibility \[[@CR13], [@CR14]\].

The C677T (rs1801133, Ala222Val) and A1298C (rs1801131, Glu429Ala) are two common polymorphisms of *MTHFR* genes. C677T is in exon 4 at nucleotide 677, which is associated with the decrease of *MTHFR* activity and increased the level of homocysteine and altered the distribution of folate, while A1298C (rs1801131, Glu429Ala) is in exon 7 at nucleotide 1298, which is also related to the reduction of *MTHFR* activity but at a lower degree compared to C677T \[[@CR15]--[@CR17]\]. A number of studies indicate that C677T and A1298C polymorphisms in the *MTHFR* gene were involved in the etiology of breast cancer among the Chinese population \[[@CR18]--[@CR31]\]. However, the results from those studies remain conflicting.

In order to get more accurate results, we performed a meta-analysis. In this study, we intend to explore the possible association between two common variants of the *MTHFR* gene, C677T and A1298C, and breast cancer risk in Chinese patients. To our knowledge, this is the most comprehensive meta-analysis conducted to date with respect to the association between *MTHFR* gene polymorphisms and breast cancer risk among the Chinese population.

Materials and methods {#Sec2}
=====================

Search strategy {#Sec3}
---------------

A comprehensive search strategy was conducted towards the electronic databases including Medline, PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese), China National Knowledge Infrastructure (CNKI, Chinese), and Wangfang Database (Chinese) with keywords "breast cancer," "breast neoplasm," "methylenetetrahydrofolate reductase," "*MTHFR*," "polymorphism," and "variant" for all studies searched on the Chinese people, and there were no limitations to the language of publications. Additional studies were identified by a hand search of the references of original studies; review articles were also examined to find additional eligible studies.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Eligible studies had to meet all of the following criteria: (a) the publication was a case--control study referring to the association between *MTHFR* polymorphisms and breast cancer in Chinese people; (b) the articles must offer the sample size, distribution of alleles, genotypes, or other information for estimating the odds ratio (OR) and 95 % confidence interval (CI); (c) when multiple publications reported on the same or overlapping data, we used the most recent or largest population; and (d) the studies were published. The following exclusion criteria were used for excluding studies: (a) not a case--control study, (b) studies that contained duplicate data, (c) no usable data reported, and (d) case reports or reviews.

Data extraction {#Sec5}
---------------

Data were carefully extracted by two authors independently from each study based on the inclusion criteria mentioned above. If conflicting evaluations were encountered, an agreement was reached following a discussion; if agreement could not be reached, then a third author was consulted to resolve the debate. The following information were extracted: (a) the name of the first author, (b) year of publication, (c) city of origin, (d) the language of each study, (e) genotyping methods, (f) source of the control group, and (g) distribution of genotypes in case and control groups. We also evaluated whether the genotype distributions were in Hardy--Weinberg equilibrium.

Statistical analysis {#Sec6}
--------------------

The strength of association between the *MTHFR* C677T polymorphisms and breast cancer risk was evaluated by OR and 95 % CI according to allele contrast (T vs. C), homozygote (TT vs. CC), heterozygote (TC vs. CC), recessive (TT vs. TC/ CC), and dominant (TT/TC vs. CC) models, while the possible association between the *MTHFR* A1298C polymorphism and breast cancer risk was assessed by OR and 95 % CI according to allele contrast (C vs. A), homozygote (CC vs. AA), heterozygote (CA vs. AA), dominant (CC/AC vs. AA), and recessive (CC vs. AC/AA) models, respectively. The heterogeneity was assessed by a chi-square-based *Q* statistic test. The effect of heterogeneity was quantified by using the *I*^2^ value as well as *P* value \[[@CR32]\]. If the *I*^2^ value \>50 % or *P* \< 0.10, then that suggests that obvious heterogeneity existed. ORs were pooled by a random effects model (the DerSimonian and Laird method) \[[@CR33]\]. Otherwise, a fixed effects model (the Mantel--Haenszel method) was used \[[@CR34]\].

The Hardy--Weinberg equilibrium \[[@CR35]\] of controls was tested by using a professional web-based program (<http://ihg2.helmholtz-muenchen.de/cgibin/hw/hwa1.pl>). If *P* \> 0.05, then it suggests that the controls followed the Hardy--Weinberg equilibrium (HWE) balance. Sensitivity analysis was performed to assess the stability of the results. A single study involved in the meta-analysis was removed each time to reflect the influence of the individual data set to the pooled ORs \[[@CR36]\]. When the Hardy--Weinberg equilibrium disequilibrium existed (*P* \< 0.05 was considered statistically significant), the sensitivity analysis was also conducted. Possible publication bias was assessed by Egger\'s test (*P* \< 0.05 was considered representative of statistically significant publication bias) \[[@CR37]\] and visual observation of funnel plot \[[@CR38]\]. All statistical tests were performed with STATA software (version 9.2, Stata Corp.). A *P* value of less than 0.05 for any test or model was considered to be statistically significant.

Results {#Sec7}
=======

Search results and study characteristics {#Sec8}
----------------------------------------

After careful examination according to the inclusion criteria, a total of 22 studies \[[@CR18]--[@CR31]\] with 6,103 cases and 7,913 controls were included in our meta-analysis: 13 studies with 3,273 cases and 4419 controls for C677T polymorphism (Table [1](#Tab1){ref-type="table"}) and 9 studies with 2,830 cases and 3,494 controls for A1298C polymorphism (Table [2](#Tab2){ref-type="table"}). The genotype distributions in the controls of all studies were consistent with HWE (all *P* \> 0.05).Table 1Characteristics of case--control studies included in *MTHFR* C667T (rs1801133, Ala222Val) polymorphism and breast cancer riskFirst authorYearCityLanguageGenotyping methodsSource of controlCasesControlsCCCTTTCCCTTTWu2012YunnanEnglishPCR-RFLPHB32301337326Gao2009NanjingEnglishPCR-RFLPPB21732712525732996Chou2006TaiwanEnglishPCR-RFLPHB73511813212033Shrubsole2004ShanghaiEnglishPCR-RFLPPB374555183387577196Inoue2008Singapore^a^EnglishPCR-RFLPPB2391202139322643Yu2007TaiwanEnglishPCR-RFLPPB5644922517025Lin2004TaiwanEnglishPCR-RFLPPB4338717314524Wu2010HeilongjiangChinesePCR-RFLPHB163529323513Yuan2009HeilongjiangChinesePCR-RFLPPB163529323513Hua2011YunnanChinesePCR-RFLPPB65219522711Kan2007YunnanChinesePCR-RFLPPB74292265299Li2009GuangdongChinesePCR-RFLPPB38171090503Qi2004BeijingChinesePCR-RFLPPB42104715910554*PCR-RFLP* PCR-restriction fragment length polymorphism, *HB* hospital-based, *PB* population-based^a^Singapore\'s Chinese peopleTable 2Characteristics of case--control studies included in *MTHFR* A1298C (rs1801131, Glu429Ala) polymorphisms and breast cancer riskFirst authorYearCityLanguageGenotyping methodsSource of controlCasesControlsAAACCCAAACCCWu2012YunnanEnglishPCR-RFLPHB3732642285Gao2009NanjingEnglishPCR-RFLPPB4781811046520512Chou2006TaiwanEnglishPCR-RFLPHB1043081729518Shrubsole2004ShanghaiEnglishPCR-RFLPPB7683114282434440Inoue2008Singapore^a^EnglishPCR-RFLPPB2251391638723441Hua2011YunnanChinesePCR-RFLPPB5042355323Kan2007YunnanChinesePCR-RFLPPB70411461328Lin2010GuangdongChinesePCR-RFLPPB45146983510Qi2004BeijingChinesePCR-RFLPPB155584144713*PCR-RFLP* PCR-restriction fragment length polymorphism, *HB* hospital-based, *PB* population-based^a^Singapore\'s Chinese people

Meta-analysis results {#Sec9}
---------------------

The main results of this meta-analysis and the heterogeneity test were shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. With regard to C677T polymorphism, significant association was found with breast cancer risk under three models (T vs. C: OR = 1.12, 95 % CI = 1.02--1.23, *P* = 0.015; TT vs. CC: OR = 1.35, 95 % CI = 1.10--1.67, *P* = 0.005 (Fig. [2a](#Fig2){ref-type="fig"}); TT vs. CC/CT: OR = 1.37, 95 % CI = 1.11--1.70, *P* = 0.004 (Fig. [2c](#Fig2){ref-type="fig"})). In the heterozygote model (TC vs. CC: OR = 1.01, 95 % CI = 0.96--1.06, *P* = 0.659) and dominant model (TT/TC vs. CC: OR = 1.06, 95 % CI = 0.99--1.1, *P* = 0.087 (Fig. [2b](#Fig2){ref-type="fig"}), no association was found between C677T polymorphism and breast cancer risk. There was no significant association found between A1298C polymorphism and breast cancer risk under all genetic models (C vs. A: OR = 0.96, 95 % CI = 0.89--1.03, *P* = 0.268; CC vs. AA: OR = 0.98, 95 % CI = 0.77--1.26, *P* = 0.899; AC vs. AA: OR = 0.95, 95 % CI = 0.88--1.02, *P* = 0.174; CC vs. AC/AA: OR = 1.00, 95 % CI = 0.78--1.28, *P* = 0.996 (Fig. [1a](#Fig1){ref-type="fig"}); CC/AC vs. AA: OR = 0.96, 95 % CI = 0.89--1.02, *P* = 0.196).Table 3Results of meta-analysis for *MTHFR* C667T (rs1801133, Ala222Val) polymorphism and breast cancer riskComparisonTest of associationModeTest of heterogeneityOR95 % CI*PPI* ^2^ (%)T vs. C1.121.02--1.230.015R069.0TT vs. CC1.351.10--1.670.005R0.00164.5TC vs. CC1.010.96--1.060.659F0.27516.7TT vs. TC/CC1.371.11--1.700.004R0.00359.3TT/TC vs. CC1.060.99--1.130.087R0.02448.9*OR* odds ratio, *CI* confidence interval, *F* fixed effects model, *R* random effects modelTable 4Results of meta-analysis for *MTHFR* A1298C (rs1801131, Glu429Ala) polymorphism and breast cancer riskComparisonTest of associationModeTest of heterogeneityOR95 % CI*PPI* ^2^ (%)C vs. A0.960.89--1.030.268F0.30315.6CC vs. AA0.980.77--1.260.899F0.8570AC vs. AA0.950.88--1.020.174F0.20027.4CC vs. AC/AA1.000.78--1.280.996F0.8920CC/AC vs. AA0.960.89--1.020.196F0.21126.2*OR* odds ratio, *CI* confidence interval, *F* fixed effects model, *R* random effects modelFig. 1**a** The forest plot describing the meta-analysis under the recessive model for the association between *MTHFR* A1298C polymorphism and the risk of breast cancer in the Chinese population (CC vs. CA + AA). **b** Begg funnel plot for publication bias test for the association between *MTHFR* A1298C polymorphism and the risk of breast cancer under the recessive model (CC vs. CA/AA). Each *point* represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. *Horizontal line* means effect size

Sensitivity analysis {#Sec10}
--------------------

Sensitivity analyses were conducted to determine whether modification of the inclusion criteria of the meta-analysis affected the final results. The statistical significance of the results was not altered when any single study was omitted, confirming the stability of the results (data not shown). So, results of the sensitivity analyses suggest that the data in our meta-analysis are relatively stable and credible.

Publication bias {#Sec11}
----------------

Funnel plot and Egger\'s test were performed to assess the publication bias. Funnel plot is relatively straightforward to observe whether the publication bias is present, and Egger\'s test was used to provide statistical evidence of symmetries of the plots. As shown in Fig. [1b](#Fig1){ref-type="fig"} (C677T polymorphism) and Fig. [2d](#Fig2){ref-type="fig"} (A1298C polymorphism), the shape of the funnel plot did not show obvious asymmetry. Similarly, the results of Egger\'s test show that no publication bias was found too (all *P* \> 0.05, data not shown).Fig. 2**a** The forest plot describing the meta-analysis under the homozygous model for the association between *MTHFR* C677T polymorphism and the risk of breast cancer in the Chinese population (TT vs. CC). **b** The forest plot describing the meta-analysis under the dominance model for the association between *MTHFR* C677T polymorphism and the risk of breast cancer in the Chinese population (TT/TC vs. CC). **c** The forest plot describing the meta-analysis under the recessive model for the association between *MTHFR* C677T polymorphism and the risk of breast cancer in the Chinese population (TT vs. TC/CC). **d** Begg funnel plot for publication bias test for the association between *MTHFR* C677T polymorphism and the risk of breast cancer under the heterozygous model (TC vs. CC). Each *point* represents a separate study for the indicated association. Log \[OR\], natural logarithm of OR. *Horizontal line* means effect size

Discussion {#Sec12}
==========

Breast cancer is one of the most common malignant tumors and leading causes of cancer-related death among females in the world, and it is a threat to women\'s health. In China, incidence showed a clear upward trend, especially in urban areas. Breast cancer incidence and mortality accounted for the top three most common female malignancy in China. Many candidate genes have been reported to be involved in breast cancer susceptibility, including *MTHFR*, *CYP19* \[[@CR39]\], *CASP8* \[[@CR40]\], *GSM1* \[[@CR7]\], *hOGG1* \[[@CR41]\], and so on. *MTHFR* is one of the primary candidate genes concerning the alteration of *MTHFR* enzyme activity which may influence the general balance between DNA synthesis, repair, and methylation processes \[[@CR15], [@CR16], [@CR42]\]. A series of studies have investigated the association between the *MTHFR* polymorphisms and breast cancer susceptibility in the Chinese people, but got controversial or inconclusive results.

Meta-analysis is a powerful tool for analyzing cumulative data of studies wherein the individual sample sizes are small and the disease can be easily masked by other genetic and environmental factors \[[@CR43], [@CR44]\]. A meta-analysis potentially investigates a large number of individuals and can estimate the effect of a genetic factor on the risk of the disease \[[@CR2]\]. The present meta-analysis, including 22 studies with 6,103 cases and 7,913 controls, explored the association between the *MTHFR* C677T and A1298C polymorphisms and breast cancer risk. Our results indicate that the *MTHFR* A1298C polymorphism is not associated with breast cancer development in the Chinese population, but a strong association between *MTHFR* C677T polymorphism and breast cancer risk was found, indicating that potentially functional *MTHFR* C677T polymorphism may play a low-penetrance role in the development of breast cancer.

Although comprehensive analysis was conducted to show the association between *MTHFR* polymorphism and risk of breast cancer, there are still some limitations that should be acknowledged. Firstly, the number of studies and the number of samples included in the meta-analysis were relatively small. Secondly, the controls were not uniformly defined. Some studies used controls that were population-based, while others used hospital-based controls, which may not be representative of the general population. Thirdly, our results were based on unadjusted estimates, while a more precise analysis should be conducted if individual data were available, which would allow for the adjustment by other co-variants including age, menopausal status, obesity, environmental factors, and lifestyle.

Despite the limitations above, our meta-analysis also had several advantages: First, a meta-analysis of the association between *MTHFR* polymorphism and breast cancer risk is statistically more powerful than any other single study. Second, a strict search strategy which combined computer-assisted search and manual search makes the eligible studies to be included as much as possible. Third, the quality of case--control studies included in the meta-analysis met our inclusion criteria and was satisfactory, and the sensitivity analysis and publication bias analysis indicated that the results of our meta-analysis are stable, credible, and convincing.

Conclusion {#Sec13}
==========

In summary, during this meta-analysis, we found that the *MTHFR* C677T polymorphism was significantly associated with breast cancer risk in the Chinese population. Meanwhile, the *MTHFR* A1298C polymorphism was not associated with breast cancer risk in the Chinese population. Considering the limited sample size and ethnicities included in the meta-analysis, further large-scale and well-designed studies are needed to confirm our results. Moreover, gene--gene and gene--environment interactions should also be considered in a future analysis.
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